

Full Length Research Paper

The efficacy of local hemostatic agents in controlling postpartum hemorrhage

Mohamed Sayed Ahmed Emarah (MD), Abeer EL Shabacy (MD), Mohamed A.EL Naggar (MD) of Obstetrics & Gynecology Department, Benha Teaching Hospital, Egypt.

Accepted 26 February, 2019

Postpartum hemorrhage (PPH) is considered as one of the most leading causes of maternal mortality all across the world, especially in developing countries. Topical hemostatic agents are utilized as adjuncts to control intraoperative bleeding in situations including: bleeding near vital organs or nerves, at needle-holes, from raw surface areas, in friable or attenuated tissues and in patients who are anticoagulated, have bleeding diatheses or have platelet dysfunction. Physical agents and biologically active agents comprise the two main categories of topical hemostatic agents. The use of local hemostatic agents for intraoperative hemorrhage control has been described by various surgical specialties including cardiovascular, otolaryngology, urology, gynecology, and others. The aim of this study is to evaluate the role of a local hemostatic agent (Gelfoam) in the control of PPH. This cross-section study was conducted at Benha Teaching Hospital, Obstetrics and Gynecology Department (Emergency Unit) for delivery. The study included 60 pregnant females who underwent cesarean section and vaginal deliveries and developed PPH. Pregnant women are at risk of PPH and blood loss during labor that cannot be always prevented. Good antenatal care help is needed in the early detection of risk factors for PPH. Those technically simple procedures such as the use of Gelfoam at the bleeding sites should have the priority in cases of PPH, because they are effective, reliable, and can be performed under easy instructions and by less trained personnel.

Keywords: Gelfoam, local hemostatic agents, postpartum hemorrhage.

INTRODUCTION

Postpartum hemorrhage (PPH) is considered one of the most leading causes of maternal mortality all across the world, especially in developing countries [1]. It occurs either due to placental site bleeding or traumatic lacerations of the female genital tract. Many measures are used to control PPH including uterine massage, uterotonics, bimanual or aortic compressions, intrauterine bags or catheters, compression sutures, and devascularization of the uterus [2].

Topical hemostatic agents are utilized as adjuncts to control intraoperative bleeding when standard surgical

techniques (such as suturing, cautery or pressure) are insufficient or impractical to implement [3].

The use of local hemostatic agents (LHAs) for intraoperative hemorrhage control has been described by various surgical specialties including cardiovascular, otolaryngology, urology, and others [4].

The use of LHAs in gynecologic surgery have been reported including laparoscopy, myomectomy, oncologic debulking, and inguinal lymphadenectomy [5].

The basic mechanism of action of passive (mechanical) hemostatic agents is to provide a physical structure around which the platelets can aggregate and form a clot [6], whereas the biologically active (physical) topical hemostatic agents stimulate the coagulation cascade, primarily through the transformation of fibrinogen to fibrin by thrombin's enzymatic action [7]. Fibrin sealants, a

category of hemostats that are designed to mimic the final steps of the blood coagulation cascade, form a stable, physiologic fibrin clot [8].

The aim of this study was to evaluate the role of LHA (Gelfoam) in the control of PPH.

PATIENTS AND METHODS

This is a cross-section study conducted at Benha Teaching Hospital, Obstetrics and Gynecology Department (Emergency Unit) for delivery. The study included 60 pregnant females who underwent cesarean section (CS) and vaginal deliveries and developed PPH.

Inclusion criteria

1. Maternal age ranged from 18 to 45 years.
2. Gestational age between 37 and 40 weeks.
3. All cases were normotensive.

Exclusion criteria

Pregnant women having any medical disorders such as chronic hypertension, diabetes mellitus, renal diseases, cardiac diseases, and also cases of twin pregnancy.

Women fulfilling the inclusion criteria were subjected to complete history-taking, general, abdominal, and vaginal examination. Preoperative investigations were done including complete blood count and coagulation profile (prothrombin time, partial thromboplastin time, international normalized ratio) and obstetric ultrasonography.

Procedure

Gelfoam absorbable-gelatin sponge is a mechanical hemostatic agent used locally at the site of bleeding (inside the uterine cavity in case of uterine atony, at placental site bleeding, outside the uterine cavity, on the uterine suture or on the complicated obstetric genital lacerations).

We cut the sponge to fit the size of the bleeding site and hold it in place for few minutes.

Curaspon is a sterile hemostatic absorbable gelatin sponge, STANDARD-REF CS-010 80×50×10 mm (CuraMedical B.V., Assendelft, The Netherlands). Curaspon gelatin sponge has a porous structure that activates the thrombocytes at the moment blood comes in contact with the matrix of the sponge, this causes the thrombocytes to release a series of substances that promote their aggregation at the same time as their surfaces change character, thus enabling the formation of the fibrin.

In case of uterine atony, we cut the Gelfoam sponge in fingers and applied them in the uterus compressing it and added intrauterine gauze pack for 24 h. In case of failure

to control bleeding with LHAs, we proceeded to uterine devascularization procedure and uterine artery ligation.

The following observations were recorded for every case. Vital signs (pulse rate, temperature, and blood pressure), uterine contractility, need for blood transfusion, need for surgical intervention such as uterine artery ligation.

RESULTS

We included twelve cases of vaginal delivery and 48 cases of CS.

Figure 1 shows that the percentage of cases that showed stoppage of bleeding with the use of Gelfoam was 73.3% and those proceeded to bilateral ut. A. ligation were 26.7%.

Figure 2 shows that the percentage of cases who did not need blood transfusion was 86.7%, and those who needed were 13.3%.

Table 1 shows statistically significant difference between stoppage of bleeding with Gelfoam and stoppage of bleeding after proceeding to bilateral ut. A. ligation, according to the indication to use Gelfoam.

Table 2 shows statistically significant difference between stoppage of bleeding with Gelfoam use and stoppage of bleeding after proceeding to bilateral ut. A. ligation, according to number of pieces used.

Table 3 shows highly statistically significant difference between stoppage of bleeding with Gelfoam and stoppage of bleeding after proceeding to bilateral ut. A. ligation, according to need for blood transfusion.

DISCUSSION

PPH plays a major role in maternal morbidity and mortality, especially in developing countries [1]. It represents a risk that attends every delivery, and is an impending danger to every child-bearing woman in the world [9].

The prediction of PPH using antenatal risk assessment is poor, only 40% of women developing PPH have an identified risk factor develop PPH [10].

However, with changes in the obstetric population (e.g., increased mean maternal age at childbirth, increasing number of women with complex medical disorders becoming pregnant, increasing maternal obesity, and macrosomic infants) and advances in technology (e.g., assisted reproduction leading to an increased rate of multiple pregnancy, increasing CS rates leading to placenta previa and its sequelae), some of these risk factors may become more important and others less important [11].

In the future, women with these risk factors should be transferred to centers with transfusion facilities and an ICU for delivery, if they are not available locally [12].

A variety of techniques have been described to control the bleeding associated with placenta previa. The B-Lynch suture and the multiple square suturing technique,




Figure 4. Pie chart of the result distribution of the study group.




Figure 5. Pie chart of the need for blood transfusion distribution of the study group.

intrauterine package by pads or balloon devices, vessel ligation either of the uterine or the internal iliac arteries, may provide hemostasis [13].

The use of LHAs has been adopted in different surgical fields including cardiovascular, urologic, and neurologic surgery. These agents have been poorly evaluated in gynecologic surgery and even less in obstetric surgery [14].

Callaghan et al. (2010) [15], *Kramer et al.(2011)* [16], *Satapornteera et al.(2012)* [17], and *Markova et al.(2012)* [18] failed to demonstrate a clear impact of aging on the PPH rate. Older mothers had the highest percentage for cesarean delivery, placenta previa, retained placenta tissues, macrosomia, uterine rupture, and more frequent medical complications. Increasing maternal age has been consistently described to be a substantial risk factor in all registers of obstetric hysterectomy for PPH.

Thus all the above mentioned facts emphasize the importance of not deferring pregnancy to an older age to prevent exposure of the mothers to the risk of pregnancy in old age.

The study showed that the percentage of cases who are PI is 23.3%, P2 (20%), P3 (16.7%), P4 (3.3%), and PG (36.7%) of parity, showing few number of cases with high parity in this study. Also, *Vyas and Saha, (2013)* [19] did not demonstrate any relation between multiparity and PPH.

Lamina MA and Ikhile, (2015)[20] have reported an association between grand multiparity and PPH. However, *Lutomski et al. (2012)* [21], *Satapornteera et al.(2012)* [17], and *Sosa et al. (2009)* [22] reported that multiparity was not a risk factor probably due to few numbers of women with actually higher numbers of deliveries.

Table 1. Comparison between stoppage of bleeding with the use of Gelfoam and stoppage of bleeding after proceeding to bilateral ut. A. ligation, according to the indication to use Gelfoam.

Indication to use Gelfoam	Outcome [n (%)]		χ^2	P value
	Bleeding stop	Bleeding stop after bilateral ut. A. ligation		
Atony	10 (22.7)	8(50.0)	14.545	0.006
Placenta previa	2 (4.5)	8 (50.0)		
Placental site bleeding	12 (27.3)	0 (0.0)		
Suture oozing	8 (18.2)	0 (0.0)		
Vaginal laceration	12 (27.3)	0 (0.0)		
Total	44 (100.0)	16 (100.0)		

Table 2. Comparison between stoppage of bleeding with the use of Gelfoam and stoppage of bleeding after proceeding to bilateral ut. A. ligation, according to number of pieces used.

Number of pieces used	Outcome [n (%)]		χ^2	P value
	Bleeding stop	Bleeding stop after bilateral ut. A. ligation		
1.00	26 (59.1)	0 (0.0)	12.273	0.002
2.00	16 (36.4)	8 (50.0)		
3.00	2 (4.5)	8 (50.0)		
Total	44 (100.0)	16 (100.0)		

Table 3. Comparison between stoppage of bleeding with the use of Gelfoam and stoppage of bleeding after proceeding to bilateral ut. A. ligation, according to need for blood transfusion.

Need for blood transfusion	Outcome [n (%)]		χ^2	P value
	Bleeding stop	Bleeding stop after bilateral ut. A. ligation		
No	44 (100.0)	8 (50.0)	12.692	<0.001
Yes	0 (0.0)	8 (50.0)		
Total	44 (100.0)	16 (100.0)		

Kramer et al.(2011) [16] and *Prata et al.(2011)* [23] reported that primiparity was a significant risk factor for PPH.

Kramer et al. [16] concluded that primiparous women were more at risk, as they were predisposed to prolonged labor, operative vaginal deliveries, perineal trauma, and uterine atony [24].

Our study showed that cases with previous CS represented 36.7%, with ongoing CS was 43.3% and vaginal delivery was 20% of the mode delivery, showing that PPH can complicate any labor, not only cases with previous CS.

Knight et al.(2009) [25] showed that, previous delivery by CS is associated with increased risk of PPH, abnormal placentation, peripartum hysterectomy, and uterine rupture.

The use of LHAs has been reported in urologic, neurologic, and cardiovascular surgery, as well as in other surgical fields. Nevertheless, its use in obstetrics is rarely reported, and the information we relay on is merely based on case reports and case series [14].

Portilla et al.(2013) [26] described the use of a LHA Surgicel (oxidized regenerated cellulose, plant origin) for the management of PPH due to bleeding of the placental

bed in patients undergoing CS due to placenta previa, and reported an inverse association between the use of LHAs in patients with PPH due to bleeding of the placental bed and the need to perform an emergency obstetric hysterectomy. In addition to the use of LHA, there was a significant reduction in the mean duration of hospital stay, use of hemoderivatives and admission to the ICU [26].

Whiteside *et al.* (2010) [27] described the use of the topical hemostatic agent, Tisseel a fibrin sealant, in a case study where it was applied to vulval and vaginal bleeding lacerations in a patient who delivered vaginally and was complicated by obstetric genital lacerations. The patient showed good, sustained response, and stopped bleeding within 10 min [27].

Our study showed that by using onepiece (43.3%), two pieces (40%) and three pieces (16.7%) number of pieces the bleeding stopped in 73.3% of the patients., but after preceding to bilateral ut. A. ligation, bleeding stopped in 86.7% of the patients., 26.7% of the patients needed a blood transfusion, whereas 13.3% of the patients did not need a blood transfusion.

Fuglsang and Petersen, (2010) [28] evaluated the effect of hemostatic fleece Tacosil (a fibrin sealant patch) when the fleece was applied directly onto the bleeding surfaces of the lower uterine segment during CS in patients with placenta previa. They concluded that in patients with PPH during CS due to placenta previa, the use of a LHA on the bleeding surface is technically easy, and suggest that this procedure should be considered in these cases.

Law *et al.* (2010) [29] reported a case report of a 35-year-old woman who had PPH, despite the use of uterotonics 2 h after cesarean delivery for major placenta previa. On relaparotomy, heavy oozing from the placental site was found. Difficult accessibility and profuse bleeding prompted the consideration of an alternative treatment with the topical application of hemostatic gel, Floseal, over the lower segment, which achieved hemostasis within minutes. Floseal is a type of hemostatic matrix that contains a combination of human thrombin solution and gelatinbased matrix from bovine collagen. They concluded that Floseal hemostatic gel is easily applicable and provides quick and effective hemostatic control in the lower segment, where surgical intervention may be difficult [29].

CONCLUSION

It can be concluded that pregnant women are at risk of PPH that cannot be always prevented, as it occasionally occurs in women who have no apparent risk factors.

It is important to highlight that technically simple procedures such as the use of Gelfoam at the bleeding sites should have the priority in cases of PPH, because they can be performed under easy instructions and by less trained personnel. Researches including more cases

should be performed for more evaluation of Gelfoam.

Conflicts of interest None declared.

REFERENCES

- Callaghan WM, Kuklina EV, Berg CJ. (2010): Trends in postpartum hemorrhage: United States, 1994–2006. *Am J Obstet Gynecol*; 202:353.e1–6.
- Chiara O, Cimbanassi S, Bellanova G, Chiarugi M, Mingoli A, Olivero G, *et al.*, (2018): A systematic review on the use of topical hemostats in trauma and emergency surgery. *BMC Surg.*;18(1):68.
- Dunkerton SE, Jevé YB, Walkinshaw N, Breslin E, Singhal T. (2018): Predicting Postpartum Hemorrhage (PPH) during Cesarean Delivery Using the Leicester PPH Predict Tool: A Retrospective Cohort Study. *Am J Perinatol*;35(2):163-169.
- Dunkerton SE, Jevé YB, Walkinshaw N, Breslin E, Singhal T. (2018): Predicting Postpartum Hemorrhage (PPH) during Cesarean Delivery Using the Leicester PPH Predict Tool: A Retrospective Cohort Study. *Am J Perinatol*; 35(2):163-169.
- Fuglsang K, Petersen LK.(2010): New local hemostatic treatment for postpartum hemorrhage caused by placenta previa at cesarean section. *Acta Obstet Gynecol Scand*; 89:1346–1349.
- Fukami T, Koga H, Goto M, Ando M, Matsuoka S, Tohyama A, *et al.*,(2019): Incidence and risk factors for postpartum hemorrhage among transvaginal deliveries at a tertiary perinatal medical facility in Japan. *PLoS One.*; 14(1): e0208873.
- Galanakis I, Vasdev N, Soomro N. (2011): A review of current hemostatic agents and tissue sealants used in laparoscopic partial nephrectomy. *Rev Urol*;13(3):131-8.
- Jakub JW, Terando AM, Sarnaik A, Ariyan CE, Faries MB, Zani S, *et al.*,(2016): Training High-Volume Melanoma Surgeons to Perform a Novel Minimally Invasive Inguinal Lymphadenectomy: Report of a Prospective Multi-Institutional Trial. *J Am Coll Surg.*;222(3):253-60.
- Kandeel M, Sanad Z, Ellakwa H, El Halaby A, Rezk M and Ibrahim Saif (2016): Management of postpartum hemorrhage with intrauterine balloon tamponade using a condom catheter in an Egyptian setting. *International Journal of Gynecology and Obstetrics*; 135: 272-5.
- Knight M, Callaghan WM, Berg C, Alexander S, Bouvier-Colle MH, Ford JB, *et al.*(2009): Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative Group. *BMC Pregnancy Childbirth*; 9:55.
- Kramer MS, Dahhou M, Vallerand D, Liston R, Joseph KS.(2011): Risk factors for postpartum hemorrhage: can we explain the recent temporal increase? *J Obstet Gynaecol Can* 2011; 33:810–819.

- Labarta FJR, Recarte MPP, Luque AA, Prieto LJ, Martin LP, Leyte MG et al (2016):* Outcomes of pelvic arterial embolization in the management of postpartum haemorrhage: a case series study and systematic review. *ejog*; 206:1221.
- Lamina MA and Ikhile M (2015):* A TenYear Review of Primary Postpartum Haemorrhage at a University Teaching Hospital, Sagamu, Nigeria. *OJOG*; 5:3.
- Law LW, Chor CM, Leung TY. (2010):* Use of hemostatic gel in postpartum hemorrhage due to placenta previa. *Obstet Gynecol*; 116:528–530.
- Lutomski J, Byrne B, Devane D, Greene RA.* Increasing trends in atonic postpartum haemorrhage in Ireland: an 11-year population-based cohort study. *BJOG* 2012; 119:306–314.
- Markova V, Srensen JL, Holm C, Norgaard A, Langhooft-Roos J. (2012):* Evaluation of multiprofessional obstetric skills training for postpartum hemorrhage. *Acta Obstet Gynecol Scand*; 91:346–352.
- Maswime S and Buchman E (2017):* A systematic review of maternal near miss and mortality due to post-partum hemorrhage. *Int J Gynecol Obstet*; 137:1-7.
- McClintock C and James AH.(2011):* Obstetric hemorrhage. *J Thromb Hemost*; 9:1441–1451.
- Portilla D, Hernandez-Giraldo C, Moreno B, Quijano F, Hoyos LR, Angarita AM et al (2013):* A local hemostatic agent for the management of postpartum hemorrhage due to placenta previa and placenta accreta. *Arch Gynecol Obstet*; 288: 543-549.
- Portilla D, Hernandez-Giraldo C, Moreno B, Quijano F, Hoyos LR Angarita AM, et al. (2013):* A local hemostatic agent for the management of postpartum hemorrhage due to placenta previa and placenta accreta: a cross-section study. *Arch Gynecol Obstet*; 288:543– 549.
- Prata N, Hamza S, Bell S, Karasek D, Vahihnia F, Holston M.(2011):* Inability to predict postpartum hemorrhage: insight from Egyptian intervention data. *BMC Pregnancy Childbirth* 2011; 11:97.
- Revelli L, Tempera SE, Bellantone C, Raffaelli M, Lombardi CP (2016):* Topical Hemostatic Agents. Minimally Invasive Therapies for Endocrine Neck Disease; 249-259.
- Satapornteera P, Arj-Ong S, Mist MA, Aswakul O. (2012):* Factors associated with early postpartum hemorrhage of singleton pregnancy in Maharat Nakhou Ratchasima Hospital. *Thai J Obstet Gynecol*; 20:21–28.
- Sosa CG, Althabe F, Belizan JM, Puekens P.* Risk factors for postpartum hemorrhage in vaginal deliveries in a Latin-American population. *Obstet Gynecol* 2009; 113:1313–1319.
- Struss A (2018):* Peripartum hysterectomy. *Hysterectomy*; 95:1189-1202.
- Su CW. (2012):* Postpartum hemorrhage. *Prim Care Clin Office Pract*; 39:167–187.
- Vyas KS and Saha SP. (2013):* Comparison of hemostatic agents used in vascular surgery. *Expert Opin Biol Ther.*; 13(12):1663-72.
- Vyas KS and Saha SP.(2013):* Comparison of hemostatic agents used in vascular surgery. *Expert Opin Biol Ther*; 13(12): 1663-72.
- Whiteside J, Asif RB, Novello RJ.(2010):* Fibrin sealant for management of complicated obstetric lacerations. *Obstet Gynecol*; 115:403–404.